Publication
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.
Barbara Burtness, Ari J Rosenberg, Benoit Calderon, Sun Min Lim, Muh-Hwa Yang, Shau-Hsuan Li, Shigenori Kadowaki, Paul L Swiecicki, Jessica L Geiger, William Ince, Dennis Hahn, Ye Guo, Douglas Adkins, Robert Metcalf, Myung-Ju Ahn, Ammar Sukari, Irene Braña, Bhumsuk Keam, Hideki Tanaka, Siddharth Sheth, Marc Oliva, Xuesong Lyu, Joshua C Curtin, Kiichiro Toyoizumi, John Xie, Mark Wade, Brooke Diorio, Aastha Kapoor, Emrullah Yilmaz, Mahadi Baig, Priya Kim, Remy B Verheijen, Sujay Shah, Kevin J Harrington, OrigAMI-4 Cohort 1 Investigators
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Single-agent paclitaxel or cetuximab after immune checkpoint inhibitor (ICI) and chemotherapy demonstrated objective response rates (ORRs) of 21%-24% in recurrent/metastatic (R/M) head/neck squamous cell cancer (HNSCC). Epidermal growth factor receptor (EGFR) and MET are overexpressed in R/M HNSCC.…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT06385080registry_reference1.00
Registered trialsNCT06385080
Curated evidence
Evidence citing this paper (0)
Data not yet available